Friday, November 30, 2012

BREAKING NEWS: Grand jury sets sights on compounding pharmacy


Meningitis Lawsuits: Federal Judge Allows Meningitis Lawsuits Against New England Compounding Center (NECC) to Proceed Read more: http://www.sfgate.com/business/prweb/article/Meningitis-Lawsuits-Federal-Judge-Allows-4081686.php#ixzz2Dm7vf3r4


Published 8:50 p.m., Friday, November 30, 2012
 Bernstein Liebhard LLP continues to investigate meningitis lawsuits on behalf of alleged victims of NECC’s epidural steroid injections.
New York, New York (PRWEB) November 30, 2012
A federal judge in Massachusetts has ruled that meningitis lawsuits filed against the New England Compounding Center (NECC) may proceed, and said evidence in the cases must be preserved, Bernstein Liebhard LLP reports. In a decision announced yesterday, U.S. District Judge Dennis Saylor also said he would consolidate about a dozen meningitis lawsuits currently pending in federal court in Boston that have been filed by alleged victims of NECC epidural steroid injections. NECC had asked Judge Saylor to delay the cases in lieu of a decision next year by the Judicial Panel on Multidistrict Litigation (JPML) on whether all federally-filed meningitis lawsuits pending against the company should be consolidated in a single federal court for pretrial proceeding. (Cole v. New England Compounding Pharmacy, 12- 12066,


Read more: http://www.sfgate.com/business/prweb/article/Meningitis-Lawsuits-Federal-Judge-Allows-4081686.php#ixzz2Dm8Bb48n

December DEA Conference on Preventing Drug Diversion Open to Pharmacy Personnel in Indiana


November 28, 2012 02:17 PM

Topics:
Drug Enforcement Administration (DEA) is offering two regional one-day Pharmacy Diversion Awareness Conferences (PDAC) in Indianapolis, IN, one on Saturday, December 8, 2012, and another on Sunday, December 9, 2012. Each one-day conference is open to pharmacy personnel (pharmacists, pharmacy technicians, or loss prevention personnel) who are employed by pharmacies or hospitals/clinics that are registered with DEA in the state of Indiana. The conference is designed to assist pharmacy personnel in identifying and responding to potential diversion activity. Location details, a conference agenda, and a link to the online registration form are available in a DEA notice. There is no registration fee for these conferences. Upon completion of the one-day conference, pharmacists and pharmacy technicians will receive 6.5 continuing pharmacy education hours (0.65 CEUs).

Source found here

Washington State Department of Health Pharmacy Compounding Standards


Pharmacy Compounding Standards

Standards for Pharmacist/Pharmacies Compounding Drug Products

  • Pharmacists may compound drugs in very limited quantities prior to receiving a valid prescription for an individual based on past routine prescribing patterns.
  • The patient and prescriber must authorize the use of a compounded product if substituted for a commercially available product. The prescriber’s authorization is in addition to signing the substitution permitted side of the written prescription, or advising the substitution when a verbal prescription is issued. The prescriber must document the authorization on the prescription or in the patient’s medication record.
  • Drugs/substances used for compounding must meet official compendia requirements.
  • The compounding of inordinate amounts of drugs, relative to the practice site, in anticipation of receiving prescriptions without any historical basis is considered manufacturing.
  • Pharmacists/Pharmacies shall not offer compounded drug products to other state-licensed persons or commercial entities for subsequent resale, except in the course of professional practice for a practitioner to administer to an individual patient.
  • Compounding pharmacies/pharmacists may advertise or otherwise promote the fact that they provide prescription compounding services; however, they shall not solicit business (e.g., promote, advertise, or use salespersons) to compound specific drug products.
  • Records and Reports related to Compounding Procedures or other records required by Chapter 246-878 WAC must be retained for at least two years. This is consistent with all prescription records (WAC 246-869-100).
  • All records must be readily available at the pharmacy/establishment for authorized inspection during the retention period. As part of the inspection, the records are subject to photocopying or other means of reproduction.
  • Compounding records may be kept either in its original format or as true copies, such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. 
Source found here

CA Board of Pharmacy to hold special board meeting RE: legislative proposal for compounding pharmacies on December 13, 2012


Special Board of Pharmacy Meeting Announced
November 21, 2012

The Board announces the convening of a special, one-day Board Meeting on December 13, 2012 in Sacramento. Two main elements for this meeting will be a regulation hearing on the adoption of two regulations for e-pedigree implementation, and refinement of a legislative proposal for compounding pharmacies. The agenda for this meeting will be released in early December (before December 3, 2012).